Online inquiry

IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12093MR)

This product GTTS-WQ12093MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12093MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2213MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ14770MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ6683MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ1691MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ4873MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ12933MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PankoMab
GTTS-WQ4520MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-936557
GTTS-WQ9246MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMMU-107
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW